Barrington Sticks to Their Buy Rating for BioScrip Inc (BIOS)

By Carrie Williams

Barrington analyst Michael Petusky maintained a Buy rating on BioScrip Inc (BIOSResearch Report) today and set a price target of $4. The company’s shares closed yesterday at $2.88.

Petusky commented:

“We continue to believe that there may be additional cost synergies beyond the initial $60 million as well as longer-term revenue synergies.”

According to TipRanks.com, Petusky is a 4-star analyst with an average return of 4.8% and a 54.0% success rate. Petusky covers the Healthcare sector, focusing on stocks such as Anika Therapeutics Inc, Varian Medical Systems, and Merit Medical Systems.

Currently, the analyst consensus on BioScrip Inc is a Moderate Buy with an average price target of $4.25.

See today’s analyst top recommended stocks >>

Based on BioScrip Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $15.67 million. In comparison, last year the company had a GAAP net loss of $15.14 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioScrip, Inc. engages in the provision of home infusion and home care management solutions. It partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. The company was founded in 1996 and is headquartered in Denver, CO.